Completed PHASE3 INTERVENTIONAL NCT00099996

Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia

A Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Heart Diseases Metabolism, Inborn Errors

Interventions Ezetimibe SCH-58235

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Dec 31, 2004 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Heart Diseases and Metabolism, Inborn Errors and is currently completed. National Heart, Lung, and Blood Institute (NHLBI) leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States